Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

Visual Abstract. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in COVE. Antinucleocapsid antibodies (anti-N Abs) are being used to diagnose prior SARS-CoV-2 infection in individuals and to determine community seroprevalence of SARS-CoV-2. In an efficacy trial of the mRNA-1273 vaccine, anti-...

Full description

Saved in:
Bibliographic Details
Published in:Annals of Internal Medicine 2022-09
Main Authors: Follmann, Dean, Janes, Holly E, Buhule, Olive D, Zhou, Honghong, Girard, Bethany, Marks, Kristen, Kotloff, Karen, Desjardins, Michaël, Corey, Lawrence, Neuzil, Kathleen M, Miller, Jacqueline M, El Sahly, Hana M, MD†, Baden, Lindsey R
Format: Article
Language:English
Subjects:
COVID-19 vaccines
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Visual Abstract. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in COVE. Antinucleocapsid antibodies (anti-N Abs) are being used to diagnose prior SARS-CoV-2 infection in individuals and to determine community seroprevalence of SARS-CoV-2. In an efficacy trial of the mRNA-1273 vaccine, anti-N Ab status was determined in participants who had prior SARS-CoV-2 infection confirmed by polymerase chain reaction or anti-N Abs. * Download figure * Download PowerPoint Abstract Background: Immunoassays for determining past SARS-CoV-2 infection have not been systematically evaluated in vaccinated persons in comparison with unvaccinated persons. Objective: To evaluate antinucleocapsid antibody (anti-N Ab) seropositivity in mRNA-1273 (Moderna) vaccinees with breakthrough SARS-CoV-2 infection. Design: Nested substudy of a phase 3 randomized, double-blind, placebo-controlled vaccine efficacy trial. (ClinicalTrials.gov: NCT04470427) Setting: 99 sites in the United States, July 2020 through March 2021. Participants: Participants were aged 18 years or older, had no known history of SARS-CoV-2 infection, and were at risk for SARS-CoV-2 infection or severe COVID-19. Substudy participants were diagnosed with SARS-CoV-2 infection during the trial's blinded phase. Intervention: 2 mRNA-1273 or placebo injections 28 days apart. Measurements: Nasopharyngeal swabs from days 1 and 29 (vaccination days) and from symptom-prompted illness visits were tested for SARS-CoV-2 via polymerase chain reaction (PCR). Serum samples from days 1, 29, and 57 and the participant decision visit (PDV, when participants were informed of treatment assignment; median day 149) were tested for anti-N Abs by the Elecsys immunoassay. Results: Among 812 participants with PCR-confirmed COVID-19 illness during the blinded phase of the trial (through March 2021), seroconversion to anti-N Abs (median of 53 days after diagnosis) occurred in 21 of 52 mRNA-1273 vaccinees (40% [95% CI, 27% to 54%]) versus 605 of 648 placebo recipients (93% [CI, 92% to 95%]). Each 1-log increase in SARS-CoV-2 viral copies at diagnosis was associated with 90% higher odds of anti-N Ab seroconversion (odds ratio, 1.90 [CI, 1.59 to 2.28]). Limitation: The scope was restricted to mRNA-1273 vaccinees and the Elecsys assay, the sample size was small, data on Delta and Omicron infections were lacking, and the analysis did not address a prespecified objective of the trial. Conclusion: Vaccination status should be considered when interpr
DOI:10.7326/M22-1300